

Earnings Presentation – 2nd Quarter, 2023

August 2, 2023



Disclaimer Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended. Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this presentation other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "thinks," and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company's expected results to differ materially from those expressed in this presentation. These factors include, among other things: general economic and business conditions, both nationally and in the regions in which we operate, including the current negative macroeconomic conditions, ongoing inflationary pressures that have significantly increased and may continue to significantly increase our expenses, the current high interest rate environment, ongoing challenging labor market conditions and labor shortages, including the current and/or potential future adverse impact of such economic conditions and other factors on our net operating revenues (including our service mix, revenue mix, payor mix and/or patient volumes) and our ability to collect outstanding receivables, as well as the potential impact on us of financial and capital market instability and/or disruptions to the banking system due to bank failures and other factors, including any potential impact on our ability to access and or obtain the return of cash and cash equivalents, and/or our ability to access credit, liquidity and capital market sources on acceptable terms or at all; the impact of current or future federal and state health reform initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the "Affordable Care Act"), and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges); the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through legislation, regulation or otherwise; the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process: risks associated with our substantial indebtedness. leverage and debt service obligations, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants; demographic changes; in or the failure to comply with, federal, state or local laws or governmental regulations affecting our business; potential adverse impact of known and unknown legal, regulatory and governmental proceedings and other loss contingencies, including governmental investigations and audits, and federal and state false claims act litigation: our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers; changes in. or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors; any security breaches, cyber-attacks, loss of data, other cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements governing the privacy and security of health information or other regulated, sensitive or confidential information, or legal requirements regarding data privacy or data protection, and the impact of the security breach announced by us on February 13, 2023, including legal, reputational, and financial risks associated with this security breach, existing and/or any future litigation associated with this security breach. potential regulatory inquiries to which we may become subject in connection with this security breach, and the extent of remediation and other additional costs that may be incurred by us in connection with this security breach, any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies: the effects related to the implementation of the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation: increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles; the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing; the impact of competitive labor market conditions and the shortage of nurses, including in connection with our ability to hire and retain gualified nurses, physicians, other medical personnel and key management, and increased labor expenses as a result of such competitive labor market conditions, inflation and competition for such positions; the non-performance of third parties with whom we contract with respect to providing hospital-based physicians and the effectiveness of our efforts to mitigate such non-performance including through acquisitions of outsourced medical specialist businesses, engagement with new or replacement providers, employment of physicians and re-negotiation or assumption of existing contracts; any failure to obtain medical supplies or pharmaceuticals at favorable prices; liabilities and other claims asserted against us, including self-insured professional liability claims: competition: trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals or via telehealth; changes in medical or other technology; any failure of our ongoing process of redesigning and consolidating key business functions, including through the implementation of a new core enterprise resource planning system, to proceed as expected or to be completed successfully; changes in U.S. GAAP; the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures; our ability to successfully make acquisitions or complete divestitures, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures; the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities; our ability to successfully integrate any acquired hospitals and/or outpatient facilities, or to recognize expected synergies from acquisitions; the impact of severe weather conditions and climate change, as well as the timing and amount of insurance recoveries in relation to severe weather events; our ability to obtain adequate levels of insurance, including cyber, general liability, professional liability, and directors and officers liability insurance: timeliness of reimbursement payments received under government programs: effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the impact of any future developments related to COVID-19 and the COVID-19 pandemic on our business, results of operations, financial condition, and/or cash flows; any failure to comply with our obligations under license or technology agreements; challenging economic conditions in non-urban communities in which we operate; the concentration of our revenue in a small number of states; our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives; any changes in or interpretations of income tax laws and regulations; and the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2022. filed with the Securities and Exchange Commission (the "SEC") on February 17, 2023 and other filings filed with the SEC.

The consolidated operating results for the three and six months ended June 30, 2023, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the reaffirmation of our guidance for calendar year 2023 (which guidance was originally included in our February 15, 2023 presentation) as set forth herein is based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements (including such guidance), or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

The hospitals, operations, and businesses described in this document are owned and operated by distinct and indirect subsidiaries of Community Health Systems, Inc.

Community Health Systems

- Tim L. Hingtgen
 Chief Executive Officer
- Kevin J. Hammons
 President and CFO

Earnings Presentation – 2nd Quarter, 2023



Near-Term Priorities



Near-term priorities designed to positively position CHS for long-term success

BCHS | 4

Income Summary

(Amounts in millions, except margin and per share amounts)	Three	Months Ended	June 30,	Six Months Ended June 3				
	2023	2022	Change	2023	2022	Change		
Net Operating Revenues	\$ 3,115	\$ 2,934	6.2%	\$ 6,223	\$ 6,044	3.0%		
Adjusted EBITDA ⁽¹⁾	\$ 373	\$ 253	47.4%	\$ 707	\$ 662	6.8%		
Adjusted EBITDA Margin ⁽¹⁾	12.0%	8.6%	340 BPS	11.4%	11.0%	40 BPS		
Net Loss per Share, Excluding Adjustments ⁽²⁾	\$ (0.22)	\$ (2.52)		\$ (0.65)	\$ (2.40)			
Shares Outstanding (Weighted and Fully Diluted)	131	129		130	128			

(1) See the Unaudited Supplemental Information contained in this presentation for a definition of Adjusted EBITDA and a reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements for the three and six months ended June 30, 2023 and 2022 (slides 15 and 16).

(2) See reconciliation of diluted net loss per share, excluding adjustments, on slide 6.

Note: Consolidated hospital count of 78 at 6/30/2023 versus 84 at 6/30/2022.

During 2Q23, no material pandemic relief funds were recognized compared to approximately \$8M in the prior year period.

Diluted EPS – Excluding Adjustments

	Three Months Ended June 30,			Six Months Ended June 30,				
	2023 2022		2023		2022			
Net loss, as reported		(0.29)	\$	(2.52)	\$	(0.68)	\$	(2.54)
Adjustments:								
Loss from early extinguishment of debt		-		-		-		0.11
Impairment and (gain) loss on sale of businesses, net		(0.02)		-		(0.13)		0.04
Expense from government and other legal matters and related costs		-		-		0.06		-
Expense from business transformation costs		0.04		-		0.04		-
Expense related to employee termination benefits and other restructuring charges		0.05		-		0.06		-
Net loss, excluding adjustments	\$	(0.22)	\$	(2.52)	\$	(0.65)	\$	(2.40)

2Q 2023 Summary

	Sequential 2Q 2023 compared to 1Q 2023	2Q 2023 compared to 2Q 2022		YTD 2023 compared to YTD 2022			
	Same Store	Consolidated	Same Store	Consolidated	Same Store		
Net Operating Revenue	1.1%	6.2%	9.2%	3.0%	5.3%		
Net Revenue per AA	-0.8%		4.1%		-1.8%		
Admissions	-0.4%	0.9%	4.8%	1.0%	4.8%		
Adjusted Admissions	2.0%	0.9%	4.9%	3.4%	7.2%		
Surgeries	1.7%	0.8%	6.2%	3.1%	8.3%		
ER Visits	1.7%	-1.5%	2.2%	0.1%	3.6%		

Non-Labor Expense

(\$ in millions,	⁾ 1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23
Supplies	\$491	\$500	\$529	\$521	\$499	\$487	\$492	\$498	\$507	\$504
Other Non-Labor	<u>\$749</u>	<u>\$740</u>	<u>\$730</u>	<u>\$743</u>	<u>\$740</u>	<u>\$757</u>	<u>\$799</u>	<u>\$805</u>	<u>\$818</u>	<u>\$829</u>
Total Non-Labor	\$1,240	\$1,240	\$1,259	\$1,264	\$1,239	\$1,244	\$1,291	\$1,303	\$1,325	\$1,333


Over 10 quarters, CHS mitigated the following material expense increases:

- New hospital openings and additional access points
- Conversion of software licensing to software as a service
- Record-high inflation


Medical specialist fees and inflation continue to pressure non-labor expenses.



Payor Mix (Consolidated)



Cash Flow & Capital Expenditures



Reported Cash Flows from Operations are provided in the Form 8-K dated August 2, 2023.

Excludes Medicare advance payments received of \$1,158 million as well as \$77 million repaid in 2020 and \$1,081 million repaid in 2021.

Capital Expenditures (\$ in millions) \$ 500 \$469 \$440 \$415 \$400 \$ 300 \$227 \$191 \$ 200 \$ 100 \$0 VTD 2022 v102023 2022 2021 2,020 2022 YTD YTD 2020 2021 2Q22 2Q23 CapEx % of Net Revenue 3.7% 3.8% 3.4% 3.2% 3.6% (includes Replacement Hospitals) **Replacement Hospitals** 1.0% 0.5% 0.1% 0.2% 0.0% % of Net Revenue

89

83

80

Number of Hospitals at Year End

#CHS | 10

84


78

(\$ in millions)	June 30, 2023	December 31, 2022			
Working Capital	\$ 1,116	\$ 896			
Total Assets	\$ 14,648	\$ 14,669			
Total Debt	\$ 11,758	\$ 11,635			
Stockholders' Deficit	\$ (1,489)	\$ (1,367)			

• At June 30, 2023, substantially all of our debt was fixed rate debt.

• Days revenue outstanding for same-store hospitals, adjusted for the impact of receivables for state Medicaid supplemental payment programs, was 57 days at June 30, 2023 and 56 days at December 31, 2022.

Debt Maturity Profile



Note: Debt maturity profile does not include \$1 billion ABL Facility

Medium-Term Financial Goals

	Medium-Term Within 3-5 Years
Net Revenue Growth	Mid-Single Digit
Adjusted EBITDA Margin	Mid-Teens
Annual Free Cash Flow	Positive
Financial Leverage (Net Debt / EBITDA)	Below 5.5x

Financial and operational goals focused on improving EBITDA margin and free cash flow as well as reducing financial leverage.



APPENDIX: Other Financial Information



Unaudited Supplemental Information

EBITDA is a non-GAAP financial measure which consists of net income (loss) attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure. is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, expense from third-party consulting costs associated with significant process and systems redesign across multiple functions (the "Business Transformation Costs") as part of the Company's multi-year initiative to modernize and consolidate technology platforms and associated processes, gain on sale of equity interests in Macon Healthcare. LLC. expense related to government and other legal matters and related costs, income during the fourth guarter of 2021 associated with the settlement of litigation for the recovery of amounts of certain professional liability claims settled in 2020 covered by third-party insurance policies, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations and the gain on sale by HealthTrust of a majority interest in CoreTrust completed during the fourth guarter of 2022. The Company has incurred and will continue to incur expenses, including but not limited to the Business Transformation Costs, associated with the Company's multi-year, transformative initiative to modernize and consolidate its technology platforms and associated processes, including the implementation of a core enterprise resource planning ("ERP") system and the redesign of associated processes. The Company has included the Business Transformation Costs as an adjustment in the calculation of Adjusted EBITDA as a result of the fact that such costs are discrete third-party consulting costs associated with this multi-year technology initiative, which costs will not continue once this initiative has been completed. The Company believes that the Business Transformation Costs are not reflective of the Company's underlying results of operations and that adjusting for the Business Transformation Costs is consistent with the intended purpose of Adjusted EBITDA in assessing the Company's operational performance and enhancing comparability of the Company's operational performance between periods. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company's hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company's executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company's consolidated results of operations and operational performance and in comparing the Company's results of operations between periods. The Company believes it is useful to provide investors and other users of the Company's financial statements this performance measure to align with how management assesses the Company's results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company's asset-based loan facility (the "ABL Facility") and the Company's existing note indentures, which is a key component in the determination of the Company's compliance with certain covenants under the ABL Facility and such note indentures (including the Company's ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). Adjusted EBITDA includes the Adjusted EBITDA attributable to hospitals that were divested during the course of such year, but in each case solely to the extent relating to the period prior to the consummation of the applicable divestiture .

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures disclosed by other companies.

Unaudited Supplemental Information

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

	Three Months Ended June 30,					Six Months Ended June 30,			
	2023			2022		2023)22	
Net loss attributable to Community Health Systems, Inc. stockholders	\$	(38)	\$	(326)	\$	(89)	\$	(327)	
Adjustments:									
Pprovision for income taxes		38		200		65		223	
Depreciation and amortization		124		133		255		261	
Net income attributable to noncontrolling interests		40		28		71		59	
Interest expense, net		207		218		414		435	
Loss from early extinguishment of debt		-		-		-		5	
Impairment and (gain) loss on sale of businesses, net		(13)		-		(35)		6	
Expense from government and other legal matters and related costs		-		-		10		-	
Expense from Business Transformation Costs		6		-		6		-	
Expense related to employee termination benefits and other restructuring charges		9		-		10		-	
Adjusted EBITDA	\$	373	\$	253	\$	707	\$	662	

Note: During the second quarter of 2022, pandemic relief funds of approximately \$8 million were recognized. During the first six months of 2022, pandemic relief funds of approximately \$55 million were recognized.